DDR2

(redirected from TKT)
Also found in: Dictionary, Acronyms.

DDR2

A gene on chromosome 1q23.3 that encodes a receptor tyrosine kinase belonging to the subfamily homologous to Dictyostelium discoideum protein discoidin (Discoidin Domain-containing Receptor); it is required for normal bone development. DDR2 regulates osteoblast differentiation and chondrocyte maturation via a MAP kinase-signalling pathway, activating the transcription factor RUNX2; it regulates remodelling of the extracellular matrix by upregulating collagenases MMP1, MMP2 and MMP13, facilitating cell migration and tumour cell invasion. DDR2 promotes fibroblast migration and proliferation, contributing to wound healing.
References in periodicals archive ?
In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union.
TKT will host a conference call/webcast, today, June 20, 2005, at 9:00 a.
Outside its focus on rare diseases, TKT intends to commercialize Dynepo, its Gene-Activated erythropoietin product for anemia related to kidney disease, in the European Union.
And unless or until this litigation is resolved in its favor, TKT will not be able to manufacture or market Dynepo (TKT's equivalent of Epogen) in the U.
Investors and security holders are able to obtain free copies of the definitive proxy statement and other documents filed by TKT with the SEC through the web site maintained by the SEC at http://www.
The acquisition of TKT is expected to significantly enhance Shire's sales and
Importantly, TKT will expand Shire's revenue generation in Europe and benefit from Shire's experience and sales teams in the renal and hematology areas.
Even if Serono's United States patent were to survive the pending appeal of the interference proceeding, we believe that TKT has substantial defenses and would expect to prevail on the merits as we did before the European Patent Office," said Michael J.
On April 21, 2005 TKT and Shire entered into an agreement under which Shire has agreed to pay $37 in cash for each share of TKT common stock, or approximately $1.
Her experience will be valuable to us as she assumes leadership of the TKT team that launched Replagal in Europe, and then achieved consistent sales growth over the past three years.
TKT is a leading biotechnology company developing and commercializing human proteins for a broad range of diseases, with a major focus on rare genetic diseases.
Chase was the corporate attorney responsible for all merger and acquisition transactions, including the merger of TKT and Shire Pharmaceuticals in April 2005.